Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

NCT02843399 · clinicaltrials.gov ↗

COMPLETED

Status

15498

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus Type 2

Sponsor

AstraZeneca

Collaborators

[object Object]